A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma - Full Text View

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

This study has been completed.

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00051181

Purpose

To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.

Condition	Intervention	Phase
Glaucoma, Angle-Closure Ocular Hypertension	Drug: Travoprost (0.004%) Drug: Latanoprost (0.005%)	Phase III

Genetics Home Reference related topics:

early-onset glaucoma

MedlinePlus related topics:

Glaucoma High Blood Pressure

Drug Information available for:

Latanoprost Travoprost

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title:	A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma.

Further study details as provided by Alcon Research:

Study Start Date:	January 2000
Study Completion Date:	June 2003
Primary Completion Date:	June 2003 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Adult patients of any race and either sex with chronic angle-closure glaucoma.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00051181

Locations


United States, Texas
	Asia
	Fort Worth, Texas, United States

Australia
	Australia
	Sidney, Australia

Sponsors and Collaborators

Alcon Research

More Information

Study ID Numbers:	C-01-38
First Received:	January 3, 2003
Last Updated:	August 4, 2008
ClinicalTrials.gov Identifier:	NCT00051181
Health Authority:	United States: Food and Drug Administration

Keywords provided by Alcon Research:

Glaucoma

POAG

OAG

OHT

Study placed in the following topic categories:

Glaucoma

Eye Diseases

Vascular Diseases

Latanoprost

Glaucoma, Angle-Closure

Travoprost

Hypertension

Ocular Hypertension

Additional relevant MeSH terms:

Therapeutic Uses

Cardiovascular Diseases

Cardiovascular Agents

Antihypertensive Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008